← Back to headlines
New Anti-Obesity Drug Retatrutida Achieves Record 30% Weight Loss in Clinical Trials
A new anti-obesity drug, retatrutida, has shown unprecedented results in clinical trials, leading to an average weight loss of 30.3% (38.5 kg) over two years in individuals with morbid obesity, marking a significant breakthrough in GLP-1 related medications.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
